Disease free survival (DFS) in breast cancer patients older than 70 years compered to younger patients groupsdoi:10.1016/S1359-6349(04)90661-1B Pajk and S Borstnar and N Snoj and T CuferEuropean Journal of Cancer Supplements
[4]Yuan, Y., Egelston, C., Colunga Flores, O., et al. CF33-hNIS-anti-PD-L1 oncolytic virus followed by trastuzumab-deruxtecan in a patient with metastatic triple negative breast cancer: a case study. Therapeutic advances in medical oncology, 15,17588359231210675. [5] Chaurasiya S, Yang...
[4]Yuan, Y., Egelston, C., Colunga Flores, O., et al. CF33-hNIS-anti-PD-L1 oncolytic virus followed by trastuzumab-deruxtecan in a patient with metastatic triple negative breast cancer: a case study. Therapeutic adv...
Gabriel Hortabagyi, MD, provides an update on data from the phase 3 NATALEE trial of ribociclib and endocrine therapy in patients with early breast cancer. Video Player is loading.This is a modal window. This video is either unavailable or not supported in this browserError...
In this prospective s... S Nakamura,H Yagata,S Ohno,... - 《Breast Cancer》 被引量: 228发表: 2010年 End Points for Adjuvant Therapy Trials: Has the Time Come to Accept Disease-Free Survival as a Surrogate End Point for Overall Survival? The intent of adjuvant therapy is to eradicate...
[7]. Francis PA, Regan MM, Fleming GF, et al: Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 372:436-446, 2015 [8]. Koga C, Akiyoshi S, Ishida M, et al: Chemotherapy-induced amenorrhea and th...
Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17 Most recurrences in women with breast cancer receiving 5 years of adjuvant tamoxifen occur after 5 years. The MA.17 trial, which was designed to ...
Huang, L., Pang, D., Yang, H. et al. Neoadjuvant–adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial. Nat Commun 15, 2153 (2024). https://doi.org/10.1038/s41467-024-45591-7....
1、R. Charles Coombes, Holly Tovey, Lucy Kilburn, et. al,Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer:The REACT Randomized Clinical Trial;[J]JAMA Oncol,2021 ,e212193.
摘要: This study determined the disease-free-survival (DFS) and overall survival (OS) of patients with stage I-III triple-negative breast cancer given adjuvant chemotherapy in a private tertiary hospital in Metro Manila, Philippines年份: 2019 ...